González-Rincón, JuliaGómez, SagrarioMartinez, NereaTroulé, KevinPerales-Patón, JavierDerdak, SophiaBeltran, SergiFernández-Cuevas, BelénPérez-Sanz, NuriaNova-Gurumeta, SaraGut, Ivo GlynneAl-Shahrour, FátimaPiris, Miguel A.García-Marco, J. A.Sánchez-Beato, Margarita2019-03-182019-03-182019González-Rincón J, Gómez S, Martinez N, Troulé K, Perales-Patón J, Derdak S et al. Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia. Sci Rep. 2019;9(1):975. DOI: 10.1038/s41598-018-37389-72045-2322http://hdl.handle.net/10230/36851Chronic lymphocytic leukaemia is the most prevalent leukaemia in Western countries. It is an incurable disease characterized by a highly variable clinical course. Chronic lymphocytic leukaemia is an ideal model for studying clonal heterogeneity and dynamics during cancer progression, response to therapy and/or relapse because the disease usually develops over several years. Here we report an analysis by deep sequencing of sequential samples taken at different times from the affected organs of two patients with 12- and 7-year disease courses, respectively. One of the patients followed a linear pattern of clonal evolution, acquiring and selecting new mutations in response to salvage therapy and/or allogeneic transplantation, while the other suffered loss of cellular tumoral clones during progression and histological transformation.application/pdfeng© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1038/s41598-018-37389-7Cancer geneticsMolecular medicineinfo:eu-repo/semantics/openAccess